Biosimilar Naming Debate Expands As Groups Jump In, Push Shared Names

A handful of consumer groups focusing on economics policies are piping up in the biosimilar debate and asking FDA not to be distracted by calls for a naming policy, but rather focus on setting up the new pathway expected to provide savings to patients. FDA recently accepted the first biosimilar application, according to Sandoz, with the announcement putting several pending policy issues, including naming, on tap. In recent weeks the American Consumer Institute Center for Citizen Research, which bills itself...